According to this recent study, immunotherapy is emerging as the standard of care for several advanced non-melanoma skin cancers (NMSCs) not amenable to surgery and radiation. Ongoing evaluation of the clinical trial landscape is needed to optimize enrollment and ensure continued innovation.
The aim of this work is to review the published data about dermoscopic features of melanoma, their histopathological correlates with regards also to genetic alterations. Particularly, this review will focus on low-CSD (cumulative sun damage) melanoma or superficial spreading melanoma, high-CSD melanoma, and nevus-associated melanoma.
This study of patients at increased risk of melanoma highlights several barriers to engagement with apps to support skin self-monitoring. The results highlight the wide-ranging and dynamic influences on engagement with mobile apps, which extend beyond app design and relate to broader contextual factors about skin self-monitoring routines and relationships with health care providers.
According to this recent study, personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention.
The aim of this recent study was to evaluate the outcomes of salvage metastasectomy after failure of systemic therapy. The study concludes that salvage metastasectomy was associated with durable survival and disease control, particularly after resection to no evidence of disease (NED), preoperative immunotherapy, and fewer lines of preoperative systemic therapy.
Authors of this recent study hypothesized that a multidimensional approach modeling both tumor and immune-related molecular mechanisms would better predict immune checkpoint blockade (ICB) response than simpler mutation-focused biomarkers, such as tumor mutational burden (TMB). The study concludes that neoantigen presentation score (NEOPS) proved the statistically strongest biomarker compared with all single-gene biomarkers, expression signatures, and TMB biomarkers evaluated in this cohort.
The Melanoma Institute Australia have released the the first stage in their Sentinel Node Biopsy Training Course on the Melanoma Education Portal. The comprehensive training program is being developed by senior clinicians from Melanoma Institute Australia in collaboration with experts from around Australia.
The MM500 meta-study aims to establish a knowledge basis of the tumor proteome to serve as a complement to genome and transcriptome studies. The melanoma proteome landscape, obtained by the analysis of 505 well-annotated melanoma tumor samples, is defined based on almost 16 000 proteins, including mutated proteoforms of driver genes. This data covers 65% and 74% of the
predicted and identified human proteome, respectively.
This recent review considers the impact of a recent update to the American Joint Committee on Cancer (AJCC) staging system, the role of sentinel node biopsy (SNB) for patients with high-risk primary melanoma and recent advances in adjuvant systemic therapies for high-risk patients.
According to this recent study, cold atmospheric plasma (CAP) facilitates doxorubicin (DOX) cytotoxic effects on melanoma cells, and affects their metastatic potential by reducing their clonogenicity.